Orthogon Therapeutics

About Orthogon Therapeutics

Orthogon Therapeutics is a biotechnology company focused on bridging frontier research with formal drug development. Their mission is to provide groundbreaking therapeutic options for common viral infections, particularly in transplant patients, through innovative drug discovery platforms.

Products & Services

Anti-Polyomavirus Drugs:A portfolio of orally administrable drugs targeting polyomaviruses (BK, JC, Merkel cell, and others) through novel mechanisms of action, focusing on unconventional drug targets like VP1 capsid, Large T-antigen, and virus-specific host targets.

BK Virus Treatment:Pioneering the first treatment for BK virus infections, specifically aimed at transplant patients, with a pipeline of promising antiviral drugs.

Specialties

Drug Discovery Platform Polyomavirus Treatments Antiviral Drug Development Machine Learning and Artificial Intelligence in Drug Development 3D Atomic Mapping of Drug-Protein Binding Target-Enriched Compound Libraries

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Oversubscribed Financing T: - FT: Oversubscribed Financing	A: 5200000 MR: - FA: $5.2M FAN: 5200000	D: 2024-12-10 FD: 2024-12-10	-

Oversubscribed Financing Latest

2024-12-10

$5.2M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Ali H. Munawar

Chief Executive Officer & Founder

M

Mark R. Spyvee

Vice President, Medicinal Chemistry

S

Stephen Weeks

Director, Structural Biology & Biophysics

R

Richard Whitley

Professor, MD

A

Anil Chandraker

MD

J

Jean Francis

MD

View 5 more team members with Pro

Unlock Full Team Directory

Recent News